The BioCentury Show
Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine.
Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues.
The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine.
Don't miss this event, every two weeks, now available as a video webcast or audio podcast.
Episodes
30 episodes
Ep. 80 - Vertex’s Winning Formula: Altshuler on Choosing the Next Breakthroughs
Vertex’s approach to research, defined over a decade ago to beat the dismal odds of success in biotech, remains core to its strategy, even as the industry evolves and technologies expand. While that strategy, which EVP and CSO David Altshuler c...
•
Season 4
•
Episode 80
•
32:26
Ep. 79 - BNP Paribas’ Moneer on Biotech’s Bull Case: M&A, PE, and Market Recovery
Since the annual J.P. Morgan Healthcare Conference in San Francisco in early January, biotech has seen a notable surge in enthusiasm, Zahid Moneer, senior managing director of investment banking at BNP Paribas, told The BioCentury Show.Mone...
•
Season 4
•
Episode 79
•
29:33
Ep. 78 - Biotech’s New Normal: SR One’s Simeon George on Adapting to Market Constraints
Biotechs need to get used to the new normal, says SR One CEO and Managing Partner Simeon George, and that will require significant adjustments to the business model. This new normal comes from an extended tough capital environment against a bac...
•
Season 4
•
Episode 78
•
31:04
Ep. 77 - AI’s Next Leap: Foresite Labs’ Vik Bajaj on Predictive Biology
Clinical trials will be launched in the next year or two to test predictions about causal biology made by artificial intelligence models, Vik Bajaj, co-founder and CEO of Foresite Labs and managing director of Foresite Capital Management, belie...
•
Season 4
•
Episode 77
•
35:29
Ep. 76 - FDA Inflection Point: Steve Usdin on Biopharma during Trump 2.0
All presidential transitions with a change of party come with disruption and threats as well as opportunities. But this one, in particular with regard to the implications for FDA, is different from all those Steve Usdin has been covering in his...
•
Season 4
•
Episode 76
•
34:01
Ep. 75 - PBMs, IRA, RFK Jr: A Conversation With Rep. Jake Auchincloss
Rep. Jake Auchincloss (D-Mass.), an influential voice in Congress on life sciences issues, gained stature last week when he was appointed to serve on the Energy & Commerce Committee, giving him a seat at the table for debates over legislati...
•
Season 4
•
Episode 75
•
36:04
Ep. 74 - Chris Bardon on Biotech’s Recovery: Valuations, Obesity Drugs, and M&A
Specialist public investors are doing their best to hold up the sector, but biotech still has to wash out many of the lower quality companies that were funded during the boom and ended up driving the generalists away, said MPM Bioimpact's Chris...
•
Season 4
•
Episode 74
•
34:03
Ep. 73 - Resilience and the CEO’s Paradox: Aoife Brennan on Leading in Biotech
Leading biotech companies through the turbulence of the past few years and the uncertainty of the next ones takes not just resilience, but an ability to grapple with the CEO’s paradox, according to Climb Bio CEO Aoife Brennan. This paradox requ...
•
Season 3
•
Episode 73
•
32:12
Ep. 72 - Outlook for Biotech M&A and Financing: Sidley's Robert Darwin
With new governments both side of the pond, capital markets picking up, and some geopolitical overhang, there’s a mixed feast for biotech, with a net trend to the positive, says Sidley Austin’s Robert Darwin, who specializes in global M&A a...
•
Season 3
•
Episode 72
•
35:54
Ep. 71 - Pazdur Unplugged: FDA Director Richard Pazdur on the Past, Future of Cancer Treatments
Richard Pazdur, director of FDA’s Oncology Center of Excellence, joined FDA in 1999. Looking back on his 25th anniversary, he draws a line between unpopular decisions at the start of his tenure and a surge in cancer drug development over the la...
•
Season 3
•
Episode 71
•
41:44
Ep. 70 - Trends in Global Biopharma Deals: Lazard’s Kingston and Raine
With most of the highly attractive late-stage assets already scooped up, pharmas are turning their sights to Phase II companies, and lining up their case to make an attractive offer and move fast. About 40% of the M&A deals in 2023-24 were ...
•
Season 3
•
Episode 70
•
33:56
Ep. 69 - Lee Fleisher: An Insider’s Account of CMS’s Alzheimer’s Coverage Decisions
CMS’s controversial decision to restrict access to Alzheimer’s mAb treatments, including Aduhelm, approved under FDA’s accelerated pathway was a unique case that is unlikely to set a precedent, former CMS CMO Lee Fleisher told BioCentury. “I do...
•
Season 3
•
Episode 69
•
34:36
Ep. 68 - Inside BeiGene: CEO John Oyler on Owning the Drug Development Process
Few CEOs have built a $20 billion biotech in under 15 years, as John Oyler has with BeiGene, managing to stay in that market cap band even through the downmarket. His strategy, to own clinical trials and manufacturing early on, looks particular...
•
Season 3
•
Episode 68
•
35:08
Ep 67 - AAM's Craig Burton on Opportunities, Challenges of U.S. Biosimilars Market
There is good news in this year’s Association for Accessible Medicines report on savings from biosimilars, including a 30% increase over the last year in savings attributed to biosimilars. The report also explores the economic, policy and regul...
•
Season 3
•
Episode 67
•
28:51
Popular Episode - Bob Nelsen on AI, China and the IRA
This is a previously recorded episode of The BioCentury Show from February 22, 2024. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all pr...
•
Season 3
•
35:33
Ep. 66 - Jane Grogan on Building Biogen’s Growth Engine
As Jane Grogan anticipates the unmet needs in patients five years from now, she’s harnessing a wave of interest in targeting B cells as a key driver of an immunology expansion at Biogen. In conversation with Editor in Chief Simone Fishburn on <...
•
Season 3
•
Episode 66
•
32:23
Ep. 65 - Astellas' Claus Zieler: Global Launches with Local Impact
As Astellas prepares to launch four products in parallel, Chief Commercial Officer Claus Zieler is balancing the complexity of this multi-faceted enterprise with a simple guiding principle: it has to work at a local level, and that will change ...
•
Season 3
•
Episode 65
•
32:27
Ep. 64 - NPC CEO John O’Brien: Why America Needs an Honest Conversation About Drug Pricing
Ignorance about the path from scientific discovery to approved drugs, high out-of-pocket costs, and a byzantine healthcare system that obscures net prices while inflating list prices have fueled policies that threaten biomedical progress, John ...
•
Season 3
•
Episode 64
•
33:36
Ep. 63 - Day One's Jeremy Bender: Building Pediatric Oncology from the Ground Up
Pediatric cancer drug development is difficult: it requires high levels of safety, involves parents as well as the patients, and has small populations that can make it difficult to achieve the revenues that reward the investment. Squaring that ...
•
Season 3
•
Episode 63
•
32:27
Ep. 62 - Rick Bright: Navigating the Avian Flu Threat
The U.S. is experiencing events that are either the first stages of a widespread avian influenza outbreak or a fire drill that will show how well the nation is prepared for an outbreak. The U.S. has not stepped up to meet the challenge, Rick Br...
•
Season 3
•
Episode 62
•
40:22
Ep. 61 - Vas Narasimhan: How New Data Fit Novartis’ Growth Plan
Differentiating on tolerability, raising the bar for efficacy and concentrating small molecule development on indications with minimal IRA exposure are all pieces of Novartis CEO Vasant Narasimhan’s strategy to break into the top pharmas by U.S...
•
Season 3
•
Episode 61
•
32:11
Ep. 60 - JMM John Maraganore: A higher bar for investment is a credit to biotech
“The bar has gotten higher because science has gotten so much better,” John Maraganore says on the latest BioCentury Show. Reflecting on the capital markets and the state of innovation, the founder and former CEO of Alnylam painted a picture of...
•
Season 3
•
Episode 60
•
36:00
Ep. 59 - Derek Lowe Unplugged: AI; Biosecure; FDA, Abortion & SCOTUS; and more
“I’m a short-term pessimist and a long-term optimist” about the potential for AI to transform drug development, Derek Lowe, author of the In the Pipeline blog, told BioCentury Washington Editor Steve Usdin on the latest BioCentury ...
•
Season 3
•
Episode 59
•
32:09
Ep. 58 - Ysios' Karen Wagner: How Europe's Biotechs Can Rise Above the Noise
It sounds obvious, but still needs saying, says Ysios Capital's Karen Wagner. “How do you rise above the noise? By having the most spectacular data.” In conversation with Editor in Chief Simone Fishburn on The BioCentury Show, Wagner d...
•
Season 3
•
Episode 58
•
30:54
